博雅生物
(300294)
| 流通市值：132.77亿 | | | 总市值：157.17亿 |
| 流通股本：4.26亿 | | | 总股本：5.04亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 448,452,537.26 | 2,651,979,506.66 | 2,190,398,869.51 | 1,540,872,254.12 |
| 营业收入 | 448,452,537.26 | 2,651,979,506.66 | 2,190,398,869.51 | 1,540,872,254.12 |
| 二、营业总成本 | 301,267,242.96 | 2,087,581,221.28 | 1,749,069,896.51 | 1,225,400,073.98 |
| 营业成本 | 144,457,836.4 | 1,252,860,597.03 | 1,094,335,017.61 | 772,068,849.7 |
| 税金及附加 | 4,016,540.27 | 20,073,412.91 | 15,696,816.81 | 10,730,878.3 |
| 销售费用 | 104,036,460.15 | 582,589,429.72 | 454,124,674.39 | 320,213,240.61 |
| 管理费用 | 37,957,181.42 | 194,854,096.46 | 159,983,633.03 | 101,013,723.06 |
| 研发费用 | 19,006,039.85 | 67,696,290.28 | 48,042,073.01 | 37,706,103.94 |
| 财务费用 | -8,206,815.13 | -30,492,605.12 | -23,112,318.34 | -16,332,721.63 |
| 其中:利息费用 | 18,610.32 | 455,592.95 | 412,004.06 | 281,614.23 |
| 其中:利息收入 | 8,270,480.83 | 31,293,144.37 | 23,811,175.94 | 16,754,540.73 |
| 加:公允价值变动收益 | 18,515,926.66 | 85,735,257.45 | 75,712,202.18 | 59,218,161.31 |
| 加:投资收益 | 1,191,885.1 | 14,014,242.6 | 41,488,575.18 | 6,954,866.38 |
| 资产处置收益 | - | 1,299,836.17 | 478,748.79 | 195,916.39 |
| 资产减值损失(新) | 660,313.48 | -329,659,853 | 64,096.17 | 194,017.56 |
| 信用减值损失(新) | -1,685,231.72 | -2,456,983.7 | -719,726.16 | -2,514,082.13 |
| 其他收益 | 8,880,607.49 | 21,894,275.3 | 18,829,417.54 | 16,295,131.14 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 174,748,795.31 | 355,225,060.2 | 577,182,286.7 | 395,816,190.79 |
| 加:营业外收入 | 1,594,051.4 | 3,797,885.03 | 2,340,629.56 | 750,844.27 |
| 减:营业外支出 | 68,871.54 | 5,311,157.12 | 4,320,692.4 | 2,975,831.49 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 176,273,975.17 | 353,711,788.11 | 575,202,223.86 | 393,591,203.57 |
| 减:所得税费用 | 24,513,132.74 | 105,563,390.25 | 101,112,893.62 | 60,964,184.58 |
| 六、净利润 | 151,760,842.43 | 248,148,397.86 | 474,089,330.24 | 332,627,018.99 |
| 持续经营净利润 | 151,760,842.43 | 215,135,907.25 | 474,089,330.24 | 332,627,018.99 |
| 终止经营净利润 | - | 33,012,490.61 | - | - |
| 归属于母公司股东的净利润 | 152,024,886.81 | 237,465,593.87 | 464,067,798.65 | 325,918,480.96 |
| 少数股东损益 | -264,044.38 | 10,682,803.99 | 10,021,531.59 | 6,708,538.03 |
| (一)基本每股收益 | 0.3 | 0.47 | 0.92 | 0.65 |
| (二)稀释每股收益 | 0.3 | 0.47 | 0.92 | 0.65 |
| 九、综合收益总额 | 151,760,842.43 | 248,148,397.86 | 474,089,330.24 | 332,627,018.99 |
| 归属于母公司股东的综合收益总额 | 152,024,886.81 | 237,465,593.87 | 464,067,798.65 | 325,918,480.96 |
| 归属于少数股东的综合收益总额 | -264,044.38 | 10,682,803.99 | 10,021,531.59 | 6,708,538.03 |
| 公告日期 | 2024-04-24 | 2024-03-23 | 2023-10-26 | 2023-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |